Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

Rutgers, The State University of New Jersey1 enrolled

Overview

This study is designed to evaluate and compare the efficacy of 3% oregano extract ointment prepared in aqueous solution versus 1% hydrocortisone ointment, a standard treatment, in decreasing the inflammation associated with mild to moderate atopic dermatitis. We plan to recruit 40 patients on the ages comprised between 2 and 17 years old and the study duration for each of the patient is 1 month.

A single-center, investigator initiated, randomized controlled, double-blind trial will be conducted to determine the effects of an oregano extract in aqueous solution versus 1% hydrocortisone in the treatment of acute-subacute pediatric atopic dermatitis (AD). We suspect that topical oregano will serve as an effective, non-steroidal AD therapy, simultaneously offering extra benefits to pediatric patients as oregano is a natural product with antimicrobial, anti-inflammatory, and antiseptic properties that lacks reports of adverse effects associated with steroids, which children have been noted to be more susceptible to.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Atopic Dermatitis

Interventions

Oregano extract creamDRUG

An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment

HydrocortisoneDRUG

An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment

Eligibility

Sex: ALLMin age: 2 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or non-pregnant female subjects aged 2-17 years of age. * Individuals must be diagnosed with acute-subacute AD regardless of the study. * Written informed consent must be obtained from all patients or caregivers. * Women of childbearing potential (WOCBP) must be willing to practice effective contraception for the duration of study treatment. * Subjects must be willing and able to comply with study conditions, properly apply or have caregivers apply topical medications to the selected body sites, as well as return to the clinic for required visits. * Subject caregivers must be willing and able to perform ADQ assessment test. Exclusion Criteria: * Individuals who are immune-compromised or suffering from infectious disease, malignant disease, are known to be HIV+ or present with a general reduced level of health. * Individuals diagnosed with underlying dermatological conditions in addition to AD. * Individuals with a chronic pre-existing disease such as diabetes mellitus or others that in the opinion of the investigator would preclude their participation in the study. * Individuals who are pregnant, nursing mothers, or subjects planning a pregnancy during the course of the study. * Subjects/caregivers who are unable to communicate or comply with study conditions due to language disability, poor mental development, or impaired cerebral function. * Individuals who are simultaneously enrolled in another clinical drug or device research study. * Individuals with a history of chronic steroid use. * Individuals needing to concurrently use topical agents, medicinal products containing corticosteroids, or immunosuppressants. * Individuals who have received systemically administered corticosteroids and/or antihistamines 2 weeks prior to the start of study. * Individuals undergoing light therapy. * Individuals who have been treated with another investigation device or drug within 30 days prior to study enrollment. * Individuals with a known allergy to oregano.

Locations (1)

Department of Dermatology. Rutgers-RWJMS

Somerset, New Jersey, United States

Outcomes

Primary Outcomes

The Clinical Efficacy Rated by the Patient or Caregiver on Days 0 and 25

This was measured with two questions. The first one referred to the description of the lesion and it included six characteristics: clear, dry, scaly, redness, cracks/opening and oozing. The second questions asked to grade how itchy was the patient. All characteristics were measured on a scale from 0 to 5 (0 none, 5 extremely bothered/losing sleep).

Time frame: From baseline to day 25

Change of the Clinical Efficacy Rated by a Study Physician

Physician was asked to grade four characteristics: erythema, infiltration/papulation, excoriation and lichenification. The grade was none (0), mild (1), moderate (2) and severe (3).

Time frame: Baseline to day 28

Histological Improvement Measured by Confocal Microscopy

Confocal microscopy was done to the patient on day 0, day 14 and day 28. Due to technical difficulties, this outcome measure was not collected.

Time frame: Baseline to day 28

Secondary Outcomes

Measure Presence of S. Aureus Colonization on Affected Skin

Bacterial culture of the affected area was done on day 0 and day 14.

Time frame: Baseline to day 14

Rate Cosmetic Acceptability of Topical Agents

The patient or caregiver rated how the product felt on their skin after applying the product, measuring the cosmetic acceptability on day 7 and 14. The scale was excellent, good, moderate and poor.

Time frame: On day 7 and 14

Rate Skin Tolerance of Topical Agents

The patient or caregiver rated how well the patient tolerated the product after applying it on day 7 and 14. The scale was excellent, good, moderate and poor.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.